AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that its first patient has completed treatment in its multi-center Phase 2 ROOT OF CANCER ovarian cancer trial. The patient has received the eighth and final dose of the study therapy under the guidance of Principal Investigator Dr. Lisa Abaid of Gynecologic Oncology Associates in Newport Beach, CA.
AIVITA’s trial calls for approximately 99 patients to be randomized in a 2:1 ratio to receive either the Company’s patient-specific cancer-stem cell targeting treatment or a control agent consisting of autologous monocytes. Eight subjects have been randomized to receive the study therapy, which is administered in a series of eight injections along with standard care. 11 subjects are currently enrolled in the study across five clinical sites, with three additional sites opening soon.
Interest amongst oncologists has been extremely high, as our therapy complements standard of care and has such a high efficacy rate. Of the eight subjects currently randomized in our trial we have been successful in manufacturing treatments for all eight, further evidencing that this technology can be quickly and reliably produced for the treatment of multiple cancer types,
said Dr. Robert Dillman,
Chief Medical Officer at AIVITA.
AIVITA is currently conducting three clinical studies investigating its platform ROOT OF CANCER therapy in patients with ovarian cancer, glioblastoma and melanoma. AIVITA uses 100% of proceeds from the sale of its ROOT of SKIN skin care line to support the treatment of women with ovarian cancer.